Beyond “One Size Fits All”: India’s AI Leap Toward Personalized Prescriptions

NEW DELHI – In a move that signals a paradigm shift for the future of Indian healthcare, the Union Minister for Science & Technology, Dr. Jitendra Singh, announced on February 19, 2026, that India’s genomics infrastructure is now the “nerve center” for a massive Artificial Intelligence (AI) push. This initiative aims to replace the traditional “one-size-fits-all” medical approach with highly personalized AI-driven prescriptions and predictive care.

Speaking at the AI Impact Summit 2026, Dr. Singh detailed how the Department of Biotechnology (DBT) is utilizing AI to decode the complex genetic makeup of the Indian population. The goal is a future where a doctor’s prescription is not just based on symptoms, but on a patient’s unique genetic code.

“Our gene sequencing work is AI-driven,” Dr. Singh stated. “Tomorrow, when we move toward personalized prescriptions, they will be based on our gene studies facilitated by Artificial Intelligence.”

The “Bio-AI Mulankur” Hubs: A New Research Era

To institutionalize this shift, Dr. Singh announced the establishment of “Bio-AI Mulankur” hubs in 2026. These integrated research platforms, supported by the Biotechnology Industry Research Assistance Council (BIRAC), will serve as a “closed-loop” ecosystem. Here, AI models will predict biological outcomes, which are then validated in laboratory settings, creating a continuous cycle of data-driven discovery.

The hubs will focus on four primary pillars:

• Genomics Diagnostics: Creating faster, cheaper tests for genetic disorders.

• Biomolecular Design: Using AI to “architect” new proteins and therapeutic molecules.

• Synthetic Biology: Engineering biological systems for sustainable manufacturing.

• Ayurveda-based Research: Applying computational tools to validate and personalize traditional Indian medicine.

Real-World Impact: TB Surveillance and Maternal Health

The transition from theory to practice is already visible in two flagship Indian programs:

1. Fighting Drug-Resistant TB: The Indian Tuberculosis Genomic Surveillance Consortium (InTGS) is currently using AI to catalogue drug-resistance mutations in Mycobacterium tuberculosis. Traditionally, confirming which drugs a TB patient is resistant to could take weeks. AI-enabled analysis of whole-genome sequencing (WGS) data has slashed this timeline to mere days, allowing clinicians to start the correct treatment immediately.

2. Safer Pregnancies: The GARBH-Ini program has identified 66 genetic markers linked to the risk of preterm birth in Indian women. By combining AI-driven ultrasound analysis with these genomic markers, doctors can now identify high-risk pregnancies much earlier, enabling interventions that save lives.

Understanding the Shift: Precision vs. Traditional Medicine

For the average consumer, the difference between current medical care and the “AI-driven” future is significant.

“In traditional medicine, if ten people have the same infection, they often get the same antibiotic,” explains Dr. Aristha Sen, a genomics researcher not involved in the government project. “But genetics dictate that one person might clear the drug too fast for it to work, while another might experience a toxic reaction. AI allows us to see these ‘invisible’ differences.”

Challenges: Data Privacy and Representation

While the promise is immense, experts urge a balanced perspective. A major hurdle in AI medicine has been “population bias.” Most global genetic databases are based on Western populations, which do not accurately reflect the 4,600+ diverse ethnic groups in India.

The GenomeIndia project—which has sequenced over 10,000 Indian genomes—is the government’s answer to this gap. However, the move toward AI-driven care raises critical questions about data privacy and the “black box” nature of AI.

“We must ensure that as we build these massive genetic repositories, the security of an individual’s most private information—their DNA—is infallible,” says Dr. Sen. “There is also the challenge of ‘explainability’; a doctor needs to know why an AI recommended a specific dosage, not just that it did.”

What This Means for You

For the health-conscious consumer, this news signals that the “future” of medicine is arriving in local clinics. While we are not yet at a point where every pharmacy visit requires a DNA swab, the infrastructure is being laid for:

• Early Screening: More accurate risk assessments for cancer, diabetes, and heart disease.

• Reduced Side Effects: Medications that are safer because they are matched to your metabolic profile.

• Cost-Effective Care: By avoiding ineffective “trial” treatments, long-term healthcare costs may decrease.

As India moves toward its “BioE3” policy—focusing on economy, environment, and employment through biotechnology—the integration of AI and genomics stands as the cornerstone of a healthier, more technologically sovereign nation.

Reference Section

• https://www.pib.gov.in/PressReleasePage.aspx?PRID=2230352&reg=3&lang=1

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.